GlycoMimetics is a privately held clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, especially those with high unmet needs.
http://ir.glycomimetics.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Sunday
LOAD TIME
0.4 seconds
PAGES IN
THIS WEBSITE
17
SSL
EXTERNAL LINKS
50
SITE IP
206.200.251.19
LOAD TIME
0.413 sec
SCORE
6.2
Investor Relations - GlycoMimetics, Inc. | ir.glycomimetics.com Reviews
https://ir.glycomimetics.com
GlycoMimetics is a privately held clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, especially those with high unmet needs.
ir.glycomimetics.com
Investor Relations - GlycoMimetics, Inc.
http://ir.glycomimetics.com/index.cfm
Innovation Today, Healing Tomorrow. Innovation Today, Healing Tomorrow. Programs & Pipeline. At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. 4:00 PM ET on Nov 04, 2016. Delayed at least 20 mins. by eSignal. Press Releases View All.
Management - GlycoMimetics, Inc.
http://ir.glycomimetics.com/management.cfm
Innovation Today, Healing Tomorrow. Innovation Today, Healing Tomorrow. Programs & Pipeline. Show all ». Rachel K. King. John Magnani, Ph.D. Vice President and Chief Scientific Officer. Helen Thackray, M.D., FAAP. Vice President of Clinical Development and Chief Medical Officer. Vice President, Corporate Development. Vice President, Technical Operations. Website Design and Development by Graphic Beans.
Press Releases - GlycoMimetics, Inc.
http://ir.glycomimetics.com/releases.cfm
Innovation Today, Healing Tomorrow. Innovation Today, Healing Tomorrow. Programs & Pipeline. GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack. GlycoMimetics to Present at Canaccord Genuity 36th Annual Growth Conference. GlycoMimetics Reports Second Quarter 2016 Results. ROCKVILLE, Md.- (BUSINESS WIRE)- GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the second quarter and six months en...ROCKV...
Board of Directors - GlycoMimetics, Inc.
http://ir.glycomimetics.com/directors.cfm
Innovation Today, Healing Tomorrow. Innovation Today, Healing Tomorrow. Programs & Pipeline. Show all ». M James Barrett, Ph.D. Chairman of the Board of Directors. Dr Barrett joined venture capital firm New Enterprise Associates. Chair of the Compensation Committee. John J. Baldwin, Ph.D. Dr Baldwin co-founded Hua Medicine in 2010 and is a member of the Board of Directors. In 2001 he co-founded Vitae Pharmaceuticals, Inc. Where he spent 33 years in various scientific and management positions.
Events & Presentations - GlycoMimetics, Inc.
http://ir.glycomimetics.com/events.cfm
Innovation Today, Healing Tomorrow. Innovation Today, Healing Tomorrow. Programs & Pipeline. Canaccord Genuity 36th Annual Growth Conference. Details on upcoming events are not yet available. Please click here. To be notified of all upcoming events. Jefferies 2016 Healthcare Conference. Speaker: Brian Hahn, CFO. Cowen and Company 36th Annual Health Care Conference. Biotechnology Industry Organization 2016 BIO CEO and Investor Conference. Speaker: Rachel King, CEO. More information can be found at http:/ ...
TOTAL PAGES IN THIS WEBSITE
17
GMI-1359 - GlycoMimetics
http://www.glycomimetics.com/programs-pipeline/gmi-1359
Innovation Today, Hope for Healing Tomorrow. Acute Myeloid Leukemia (AML). Pipeline & Technology. Events & Presentations. Financials & Filings. Data in the scientific literature and from GlycoMimetics’ pre-clinical studies suggest that targeting both E-selectin and CXCR4 could provide enhanced benefits. Data presented at the December 2011 American Society of Hematology (ASH) meeting. Two posters presented at the AACR Annual Meeting 2015 summarized research data on GMI-1359. We are exploring use of compou...
Rivipansel (GMI-1070) - GlycoMimetics
http://www.glycomimetics.com/programs-pipeline/gmi-1070
Innovation Today, Hope for Healing Tomorrow. Acute Myeloid Leukemia (AML). Pipeline & Technology. Events & Presentations. Financials & Filings. About the Rivipansel (GMI-1070) Trial. In January 2013, GlycoMimetics, Inc. completed enrollment. In the Phase 2 trial, patients treated with rivipansel experienced reductions in time to reach resolution of VOC, length of hospital stay and use of opioid analgesics for pain management, in each case as compared to patients receiving placebo. News & Events. Website ...
Benefits - GlycoMimetics
http://www.glycomimetics.com/careers/benefits
Innovation Today, Hope for Healing Tomorrow. Acute Myeloid Leukemia (AML). Pipeline & Technology. Events & Presentations. Financials & Filings. GlycoMimetics offers competitive benefits and compensation. We are committed to providing employees and their families with a comprehensive benefits package that attracts, retains, and motivates employees. Benefits offered to GlycoMimetics’ full-time employees include:. Group Life Insurance and Accidental Death and Dismemberment. Short and Long Term Disability.
Careers - GlycoMimetics
http://www.glycomimetics.com/careers
Innovation Today, Hope for Healing Tomorrow. Acute Myeloid Leukemia (AML). Pipeline & Technology. Events & Presentations. Financials & Filings. GlycoMimetics offers an exciting opportunity for excellent candidates to join a world-class biotechnology company in the heart of Maryland’s biohealth corridor. Benefits packages include competitive salaries, 401K, health and dental plans, paid vacation in addition to paid holidays, as well as an opportunity to participate in equity in the company. Click here for...
Core Values - GlycoMimetics
http://www.glycomimetics.com/about-us/core-values
Innovation Today, Hope for Healing Tomorrow. Acute Myeloid Leukemia (AML). Pipeline & Technology. Events & Presentations. Financials & Filings. At GlycoMimetics, we are focused on developing treatments that provide hope for patients with sickle cell, cancer, and other serious diseases. We are pioneers in the use of glycobiology technology. Reflecting our understanding of the roles cellular carbohydrates play in heath and disease. We possess an inner strength that allows us to remain dedicated to a purpos...
GMI-1271 - GlycoMimetics
http://www.glycomimetics.com/programs-pipeline/gmi-1271
Innovation Today, Hope for Healing Tomorrow. Acute Myeloid Leukemia (AML). Pipeline & Technology. Events & Presentations. Financials & Filings. In June 2016, GlycoMimetics announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for GMI-1271 for treatment of adult patients with relapsed or refractory AML and elderly patients aged 60 years or older with AML. About the Current Trial in AML. For more information on the trial and to find a participating site near you...
About Us - GlycoMimetics
http://www.glycomimetics.com/about-us
Innovation Today, Hope for Healing Tomorrow. Acute Myeloid Leukemia (AML). Pipeline & Technology. Events & Presentations. Financials & Filings. GlycoMimetics is a publicly traded, clinical-stage biotechnology company that utilizes novel and proprietary glycobiology technology to develop treatments for diseases, especially those with high unmet needs. Consists of industry leaders with deep experience in the pharmaceutical/biotech industry. With sickle cell, cancer, and other serious diseases.
Sitemap - GlycoMimetics
http://www.glycomimetics.com/sitemap
Innovation Today, Hope for Healing Tomorrow. Acute Myeloid Leukemia (AML). Pipeline & Technology. Events & Presentations. Financials & Filings. John Magnani, Ph.D., presented with the President’s Innovator Award. Senior Director, Medical Oncology. Acute Myeloid Leukemia (AML). Pipeline & Technology. ASH Features Data on GMI-1070 in Annual Meeting Press Conference. BIO International Convention 2013: Rachel King Interviewed By Women In Bio. ASH Features Data on GMI-1070 in Annual Meeting Press Conference.
Pipeline & Technology - GlycoMimetics
http://www.glycomimetics.com/programs-pipeline
Innovation Today, Hope for Healing Tomorrow. Acute Myeloid Leukemia (AML). Pipeline & Technology. Events & Presentations. Financials & Filings. Pipeline & Technology. In 2014. This drug candidate is currently being studied in a Phase 1/2 clinical trial as a potential treatment for AML in combination with chemotherapy. Learn more about our pipeline programs:. News & Events. Tue, Aug 16, 2016. GlycoMimetics to Present at Canaccord Genuity 36th Annual Growth Conference. Mon, Aug 08, 2016. Thu, Aug 04, 2016.
TOTAL LINKS TO THIS WEBSITE
50
Global Self Storage, Inc. (SELF)
What Not To Store. The Company currently owns and operates, through its wholly owned subsidiaries, eleven self storage properties located in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, and South Carolina. Jan 3, 2017. Global Self Storage Completes Acquisition of Tuxis Self Storage Facilities in Clinton, Connecticut and Millbrook, New York. March 12 - March 14, 2017. 29th Annual ROTH Conference. Sep 30, 2016. Sign up for email alerts. View Detailed Stock Info. View Board Of Directors.
Default Web Site Page
If you are the owner of this website, please contact your hosting provider: webmaster@ir.globalyatirim.com. It is possible you have reached this page because:. The IP address has changed. The IP address for this domain may have changed recently. Check your DNS settings to verify that the domain is set up correctly. It may take 8-24 hours for DNS changes to propagate. It may be possible to restore access to this site by following these instructions. For clearing your dns cache.
Glorious Property Holdings Ltd.
Glory
DATE OF BOARD MEETING. Monthly Return of Equity Issuer on Movements in Securities. Monthly Return of Equity Issuer on Movements in Securities. Monthly Return of Equity Issuer on Movements in Securities. POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 29, 2015. Monthly Return of Equity Issuer on Movements in Securities. NOTICE OF ANNUAL GENERAL MEETING. FORM OF PROXY ANNUAL GENERAL MEETING. Monthly Return of Equity Issuer on Movements in Securities. DATE OF BOARD MEETING.
Overview | Investor Relations | Global Logistic Properties
Make enguiries *required fields. How can we help you? By clicking submit, I hereby agree to GLP processing my personal data for the above and contacting me in accordance with its Privacy Policy. GLP Brazil Development Partners I. GLP Brazil Income Partners I. GLP Brazil Income Partners II. GLP Japan Development Venture. GLP Japan Income Partners I. US Income Partners I. Share Price and Dividend. Announcements and Press Releases. GLP at A Glance. Environmental, Social and Governance Policy. Data collected...
Investor Relations - GlycoMimetics, Inc.
Innovation Today, Healing Tomorrow. Innovation Today, Healing Tomorrow. Programs & Pipeline. At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. GlycoMimetics to Present at the Canaccord Genuity Growth Conference. View all press releases ».
投資家の皆様へ - GMOインターネット株式会社
2017年12月期 通期 決算発表 [2018年2月9日(金)]. English IR Documents ». 2017年12月期 定時株主総会 [2018年3月21日(水 祝)]. 2017年12月期 定時株主総会 招集ご通知 2.81MB. Notice of the FY2017 Annual General Meeting of Shareholders 2017年12月期定時株主総会招集ご通知(英文) 408KB. 自己株式の取得枠設定に関するお知らせ 会社法第 459 条第１項の規定による定款の定めに基づく自己株式の取得. 2018年2月9日 金 15:30 終了.
ＧＭＯクラウド株式会社
One GMO CLOUD Way. グループ会社 One GMO CLOUD. 企業理念 One GMO CLOUD. カーオーナー向けスマホアプリ LINKDrive byGMO 走るだけでポイントが貯まる クルマイレージ など3つの新機能を追加 お客様に応じた集客が可能な、店舗向けの"車両管理 集客サービス"も提供開始. GMO電子契約サービスAgree とドキュメントフレームワーク OPROARTS(オプロアーツ) が連携 Salesforce(セールスフォース) など顧客管理クラウド上で、ドキュメントの作成から管理までシームレスに. GMOクラウド、日栄インテック、中国のShenzhen Atte Smart Tech IoTを活用したスマートホーム事業における、製品の企画開発 製造 販売展開で協業. Latest News and Events. Latest News and Events.
Global Supply Chain Management Solutions - UTi Worldwide
Energy, Mining Projects. Not A Weak Link. UTi develops global integrated supply chain solutions for clients in specialized industry verticals. UTi offers a full range of global supply chain management services. UTi has decades of experience managing supply chains from end-to-end. UTi focuses on client-centric solutions that are configured to most closely fit our clients' businesses. A non-profit organization dedicated to helping those who live in desperate circumstances. Not A Weak Link. CEO Ed Feitzinge...
Gogo Inflight Internet - Investor Relations - Investor Relations Home
Investor and Analyst Day. Gogo Inc. Announces Pricing of $65 Million Senior Secured Notes Offering. Gogo Inc. Announces Launch of $50 Million Senior Secured Notes Offering. Gogo Inc. to Participate in Citi Internet, Media and Telecommunications Conference on January 5, 2017. Gogo Inc. to Participate in UBS Global Media and Communications Conference on December 6, 2016. There are currently no events scheduled. 160; 0.17. Data as of 01/11/17 4:00 pm ET. Minimum 20 minute delay. Why airlines choose Gogo.
Gold Reserve, Inc. | Investor Relations | Investor Relations
Gold Reserve Inc. has history in mining dating back to 1956 and was formed for the purpose of acquiring, exploring and developing mining properties and placing them into production. Consistent with that strategy, the Company in 1992 acquired and began developing what is now known as the Brisas gold and copper project, located in the historic Km 88 mining district of the State of Bolivar in southeastern Venezuela (the “Brisas Project”). 160; 0.03. Data as of 04/13/17 3:46 pm ET. Vancouver, BC Canada.
SOCIAL ENGAGEMENT